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Abstract
Background: Artemisinin combination therapy (ACT) is recommended for the treatment of multidrug resistant malaria in
the second and third trimesters of pregnancy, but the experience with ACTs is limited. We review the exposure of pregnant
women to the combination dihydroartemisinin-piperaquine over a 6 year period.
Methods: From April 2004–June 2009, a prospective hospital-based surveillance screened all pregnant women for malaria
and documented maternal and neonatal outcomes.
Results: Data were available on 6519 pregnant women admitted to hospital; 332 (5.1%) women presented in the first
trimester, 324 (5.0%) in the second, 5843 (89.6%) in the third, and in 20 women the trimester was undocumented. Peripheral
parasitaemia was confirmed in 1682 women, of whom 106 (6.3%) had severe malaria. Of the 1217 women admitted with
malaria in the second and third trimesters without an impending adverse outcome, those treated with DHP were more likely
to be discharged with an ongoing pregnancy compared to those treated with a non-ACT regimen (Odds Ratio OR= 2.48
[1.26–4.86]); p = 0.006. However in the first trimester 63% (5/8) of women treated with oral DHP miscarried compared to
2.6% (1/38) of those receiving oral quinine; p,0.001. Of the 847 women admitted for delivery those reporting a history of
malaria during their pregnancy who had been treated with quinine-based regimens rather than DHP had a higher risk of
malaria at delivery (adjusted OR= 1.56 (95%CI 0.97–2.5), p = 0.068) and perinatal mortality (adjusted OR= 3.17 [95%CI: 1.17–
8.60]; p = 0.023).
Conclusions: In the second and third trimesters of pregnancy, a three day course of DHP simplified antimalarial treatment
and had significant benefits over quinine-based regimens in reducing recurrent malaria and poor fetal outcome. These data
provide reassuring evidence for the rational design of prospective randomized clinical trials and pharmacokinetic studies.
Citation: Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Sugiarto P, et al. (2014) Dihydroartemisinin-Piperaquine Treatment of Multidrug Resistant
Falciparum and Vivax Malaria in Pregnancy. PLoS ONE 9(1): e84976. doi:10.1371/journal.pone.0084976
Editor: Quique Bassat, University of Barcelona, Spain
Received September 9, 2013; Accepted November 28, 2013; Published January 17, 2014
Copyright:  2014 Poespoprodjo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by the Wellcome Trust-NHRMC (Wellcome Trust ICRG GR071614MA- NHMRC ICRG ID 283321). NMA is supported by an NHMRC
Practitioner Fellowship, RNP by a Wellcome Trust Senior Research Fellowship in Clinical Science (091625) and JRP by an AusAID Australian Leadership Award. The
Timika Translational Research Facility is supported by AusAID. No funding bodies had any role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rprice@menzies.edu.au
Introduction
Malaria in pregnancy (MiP) is an major global health problem
associated with an increased risk of severe adverse events
contributing to both maternal and infant mortality [1,2]. Although
early diagnosis and prompt treatment with effective antimalarial
drugs are important interventions for reducing these adverse
outcomes [3,4], however this strategy is under threat from the
emergence and spread of multidrug resistant parasites [5]. The
World Health Organisation advocates three alternatives for the
treatment of malaria in the second and third trimesters of
pregnancy: an ACT known to be effective in the country/region, a
7 day course of artesunate plus clindamycin, or a 7 days course of
quinine plus clindamycin. In view of the lack of safety data WHO
guidelines do not recommended the use of ACTs in the first
trimester [6]. However recent evidence from clinical trials has
highlighted the adverse impact of even a single episode of malaria
in the first trimester of pregnancy and its association with
miscarriage [7]. These observations have lead some authorities
to call for a review of the safety and efficacy of artemisinin based
treatment regimens with regard to optimizing malaria the
management in early as well as late pregnancy. There is a clear
need for highly effective antimalarial treatments that can applied
safely in early pregnancy.
Experience with the use of ACTs in pregnancy is accruing,
although evidence of the public health impact of this policy is
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limited [8]. Despite this in most malaria endemic regions
antimalarial treatment of pregnant women remains reliant on
quinine, chloroquine or sulfadoxine-pyrimethamine (SP) based
regimens. However the use of these conventional treatments
become increasingly compromised by the widespread drug
resistance to chloroquine and SP [9,10].
In Papua, Indonesia, high grade resistance to chloroquine (CQ)
and sulfadoxine-pyrimethamine (SP) is prevalent in both P.
falciparum and P. vivax [11], and few options exist for the treatment
of MiP. Historically the alternative treatment has been a 7 day
course of unsupervised quinine, but evidence suggests that this is
rarely adhered to and when prescribed as an unsupervised
treatment its effectiveness falls to less than 45% [11]. In this
region previous clinical trials have demonstrated dihydroartemi-
sinin-piperaquine (DHP) to be safe and highly effective (failure
rates ,10%) in treating uncomplicated malaria from both species
in non-pregnant patients [12]. Preliminary data on the use of
piperaquine from animal reproductive toxicity studies are reas-
suring [13,14,15], but few studies have specifically documented the
safety and efficacy of DHP in pregnant women with uncompli-
cated P. falciparum malaria [16,17].
In view of the high level of multidrug resistant malaria and
malaria attributable morbidity and mortality, the local Ministry of
Health in southern Papua changed antimalarial policy for
uncomplicated malaria to DHP in March 2006, for all patients
over 5 kg in weight including pregnant women with uncompli-
cated malaria in the second and third trimesters. At the same time
the policy for the initial treatment of pregnant women with severe
malaria in the second and third trimester of pregnancy was
changed to intravenous artesunate followed with DHP. The aim of
the current study was to document the exposure of pregnant
women with malaria to DHP in order to assess their safety in both
mother and baby and impact on pregnancy outcome.
Methods
Study site
The study was carried out at Rumah Sakit Mitra Masyarakat
(RSMM) hospital, Timika, (Papua, Indonesia) a hospital servicing
a population of 200,000 people. Malaria transmission is unstable
with an annual incidence of 876 per 1000 person years, divided
61:39 between P. falciparum and P. vivax infections [18]. Clinical
drug trials in this region have shown more than 50% of patients
with either P. falciparum or P. vivax fail treatment following
chloroquine monotherapy, CQ plus SP or unsupervised quinine
[11].
Study population
The maternal mortality ratio in this region is 1,145/100,000 live
births with the infant mortality rate reaching 68 per 1,000 live
births [19]. Each year there are approximately 3,000 pregnant
women in Timika, of whom less than 40% attend antenatal care
clinic and only half deliver at the RSMM hospital [20]. As well as
local lowland Papuans, other ethnic groups are present in this
region attracted by a local mine.
Data collection
From April 2004 to June 2009, all pregnant women and
newborn infants admitted to the maternity ward at RSMM were
screened for malaria and, following written informed consent, data
were gathered prospectively using a systematic questionnaire as
described previously [9]. Maternal venous blood (5 ml) was taken
on admission, for complete blood count and blood film
examination by accredited research microscopists. Parasite counts
were determined from the number of parasites per 200 white
blood cells (WBC) on Giemsa-stained thick films and considered
negative after review of 200 high-power fields. A thin smear was
examined to confirm parasite species and quantify parasitemia if
greater than 200 per 200 WBC on the thick film. Haemoglobin
concentration was determined by electronic counter (Coulter
JTTM, USA).
All pregnant women admitted to hospital were screen for
malaria and any found to have a peripheral asexual parasitemia
were offered antimalarial treatment, irrespective of clinical signs,
species of infection or the degree of parasitaemia.
Severe malaria was defined according to the 2003 WHO
criteria {WHO, 2003 #1242}.
Maternal anemia was categorized as severe if the hemoglobin
concentration was less than 7 g/dl [21]. Neonatal adverse
outcomes (low birth weight, preterm delivery and perinatal deaths)
were defined according to WHO criteria [22]. On admission to
hospital, fever was diagnosed if women gave a history of fever
within the preceding 24 hours or had a documented axillary
temperature greater than 37.5uC. Women who gave a history of a
febrile illness during this pregnancy were regarded as having a
history of possible malaria.
Antimalarial treatment for uncomplicated malaria was admin-
istered according to hospital policy, which until March 2006 was
quinine plus clindamycin for patients with falciparum malaria and
chloroquine plus sulfadoxine-pyrimethamine for women with non-
falciparum malaria. Treatment was administered by the ward
nurse during in patient stay but was unsupervised if the patient was
discharged from hospital prior to completing treatment. Women
with manifestations of severe malaria or judged as being at risk by
the attending clinician were treated with intravenous quinine. In
March 2006 local therapeutic guidelines for both uncomplicated
and severe malaria were revised. Pregnant women with uncom-
plicated malaria due to any species of Plasmodium in the second
and third trimester of pregnancy were treated with oral
dihydroartemisinin-piperaquine. Quinine and clindamycin re-
mained the treatment of choice in the first trimester. Dihydroar-
temisinin-piperaquine (DHP) was produced by Holley Pharma-
ceutical Co, PRC, the fixed dose containing 40 mg
dihydroartemisinin and 320 mg piperaquine (ArtekinH) adminis-
tered according to body weight with a target dose of 2–4 mg/kg of
dihydroartemisinin and 16–32 mg/kg of piperaquine, once a day
for three days. During periods in which the supply of DHP was
interrupted, an alternative ACT (amodiaquine plus artesunate)
was substituted. Women with severe manifestations of malaria as
defined by the WHO guidelines {WHO, 2003 #1242}, were
treated with intravenous artesunate until they could tolerate oral
treatment with oral DHP (2nd and 3rd trimesters) or quinine (1st
trimester).
The attending physician and a research clinician prospectively
reviewed all maternity ward admissions and newborns. A
systematic interview and review of the clinical notes was used to
obtain data on maternal characteristics (maternal age, ethnic
groups, parity), clinical condition (fever and signs of severity as
defined by WHO guidelines [8]), history of febrile illness and
malaria treatment received during the current pregnancy. A
trained research nurse performed newborn physical examination
to assess clinical signs and gestational age (New Ballard Score)
[23].
Statistical analysis
Data were entered into EpiData 3.02 software (EpiData
Association, Odense, Denmark) and statistical analysis done using
SPSS vs17.0 (SPSS Inc, Chicago, Illinois). Since pregnant women
DHA-Piperaquine in Pregnancy
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could not be randomized to different treatments, comparisons
were made between maternal outcome in those exposed to DHA-
piperaquine and compared with women treated other antimalar-
ials, before and after controlling for baseline confounding factors.
Antimalarial exposure during pregnancy was evaluated according
to two analyses. The first analysis included women presenting with
peripheral parasitaemia at the time of admission. In these
individuals malaria itself is an important cause of adverse
outcomes such as abortion, premature delivery and intra-uterine
fetal death. To reduce this confounding effect the risk of adverse
events associated with drug treatment excluded women presenting
with an impending outcome prior to treatment. Women who had
no adverse outcome during an acute admission for malaria were
defined as being discharged with an ongoing pregnancy. The
second analysis included all women with a known outcome of
pregnancy to assess the risk of adversity associated with exposure
to antimalarial drugs over the prior antenatal period. The analyses
of drug exposure were restricted to the six main treatments
recommended for uncomplicated malaria (chloroquine +/2
sufadoxine pyrimethamine, oral quinine and oral DHA-piper-
aquine) and severe malaria (intravenous quinine, intravenous
artesunate and intravenous artesunate plus oral DHA-piperauine).
Categorical data were compared by x2 with Yates’ correction or
by Fisher’s exact test. Normally distributed continuous data were
compared by Student’s t test or one-way analysis of variance if
normally distributed and by Mann-Whitney U test or the
Wilcoxon signed rank test if non normally distributed. Survival
analysis with the Kaplan Meier method was used to examine the
effect of malaria treatment history during pregnancy on the
cumulative risk of malaria at delivery. Multiple logistic regression
was used to determine the adjusted odds ratios (AOR) of risk
factors for adverse pregnancy outcomes as defined in previous
analysis from the same location ; these included maternal age,
ethnic groups, parity, fever and severity of malaria [9]. In all
multivariable models, known risk factors were entered into the
model after stratifying by year of exposure.
Ethical approval
Written informed consent was gathered from all patients or in
the case of minors their guardians. Ethical approval for the study
was obtained from the ethics committees of the National Institute
of Health Research and Development, Ministry of Health,
Indonesia (KS.02.01.2.1.3431) and Menzies School of Health
Research, Darwin, Australia (04/47).
Results
Between April 2004 and June 2009, 6519 pregnant women
were admitted to the maternity ward and enrolled in the study. Of
these women 5% (322) were admitted more than once. The reason
for admission was primarily for delivery (4963/6508, 76%) with
the remaining women admitted for malaria (728, 11%) and
Figure 1. Study Profile: Acute Malaria Treatment.
doi:10.1371/journal.pone.0084976.g001
DHA-Piperaquine in Pregnancy
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e84976
T
a
b
le
1
.
P
re
g
n
an
cy
o
u
tc
o
m
e
s
in
w
o
m
e
n
w
it
h
ac
u
te
m
al
ar
ia
(2
n
d
an
d
3
rd
tr
im
e
st
e
rs
o
f
p
re
g
n
an
cy
).
P
re
g
n
a
n
cy
O
u
tc
o
m
e
C
Q
+/
2
S
P
Q
u
D
H
P
a
lo
n
e
p
v
a
lu
e
IV
Q
u
+/
2
O
ra
l
Q
u
IV
A
rt
+
D
H
P
IV
A
rt
a
lo
n
e
p
v
a
lu
e
p
v
a
lu
e
(o
ra
l
v
s
IV
)
n
=
9
7
n
=
1
7
6
n
=
4
8
5
1
n
=
9
5
n
=
2
7
9
1
n
=
8
3
A
d
m
it
te
d
fo
r
D
e
li
v
e
ry
(n
=
6
9
0
)
Li
ve
b
ir
th
s
9
9
%
(9
3
/9
4
)
9
6
%
(1
2
5
/1
3
0
)
9
7
(3
6
6
/3
7
8
)
0
.4
5
5
9
0
%
(2
7
/3
0
)
9
6
%
(4
3
/4
5
)
9
2
%
(1
2
/1
3
)
0
.6
4
0
0
.1
1
0
St
ill
b
ir
th
s
0
%
(0
/9
4
)
0
.8
%
(1
/1
3
0
)
1
.3
%
(5
/3
7
8
)
0
.4
9
1
3
.3
%
(1
/3
0
)
4
.4
%
(2
/4
5
)
0
%
(0
/1
3
)
0
.7
3
9
0
.0
7
8
Ea
rl
y
n
e
o
n
at
al
d
e
at
h
s
1
.1
%
(1
/9
4
)
3
.1
%
(4
/1
3
0
)
1
.6
%
(6
/3
7
8
)
0
.4
5
9
3
.3
%
(1
/3
0
)
0
%
(0
/4
5
)
7
.7
%
(1
/1
3
)
0
.2
3
3
0
.6
7
6
A
d
m
it
te
d
fo
r
T
re
a
tm
e
n
t
o
f
M
a
la
ri
a
(n
=
5
2
5
)1
O
n
g
o
in
g
p
re
g
n
an
cy
1
0
0
%
(3
/3
)
8
3
%
(3
8
/4
6
)
9
5
%
(1
0
2
/1
0
7
)
0
.0
2
9
8
5
%
(5
5
/6
5
)
9
2
%
(2
1
5
/2
3
4
)
9
6
%
(6
7
/7
0
)
0
.0
6
4
0
.3
4
5
St
ill
b
ir
th
s
0
%
(0
/3
)
0
%
(0
/4
6
)
0
%
(0
/1
0
7
)
-
3
.1
%
(2
/6
5
)
3
.8
%
(9
/2
3
4
)
2
.9
%
(2
/7
0
)
0
.9
0
4
0
.0
1
3
Ea
rl
y
n
e
o
n
at
al
d
e
at
h
s
0
%
(0
/3
)
6
.5
%
(3
/4
6
)
0
%
(0
/1
0
7
)
0
.0
2
6
0
%
(0
/6
5
)
0
%
(0
/2
3
4
)
0
%
(0
/7
0
)
-
0
.0
5
1
P
re
te
rm
d
e
liv
e
ry
*
0
%
(0
/3
)
2
.9
%
(1
/3
4
)
1
.2
%
(1
/8
6
)
0
.7
6
6
0
%
(0
/5
4
)
2
%
(4
/2
0
3
)
0
%
(0
/6
4
)
0
.3
0
8
0
.7
0
7
N
o
te
s:
C
Q
=
C
h
lo
ro
q
u
in
e
;
S
P
=
Su
lp
h
ad
o
xi
n
e
-P
yr
im
e
th
a
m
in
e
;
D
H
P
=
D
ih
yd
ro
ar
te
m
is
in
in
p
ip
e
ra
q
u
in
e
;
Q
u
=
Q
u
in
in
e
;
A
rt
=
A
rt
e
su
n
at
e
.
C
Q
+/
2
S
P
=
ch
lo
ro
q
u
in
e
w
it
h
o
r
w
it
h
o
u
t
Su
lp
h
ad
o
xi
n
e
-P
yr
im
e
th
am
in
e
;
IV
Q
u
+/
2
O
ra
l
Q
u
=
In
tr
av
e
n
o
u
s
Q
u
in
in
e
w
it
h
o
u
r
w
it
h
o
u
t
su
b
se
q
u
e
n
t
o
ra
l
q
u
in
in
e
.
*I
n
w
o
m
e
n
p
re
se
n
ti
n
g
b
e
fo
re
3
7
w
e
e
ks
g
e
st
at
io
n
;
1
u
n
d
o
cu
m
e
n
te
d
p
re
g
n
an
cy
o
u
tc
o
m
e
s
in
tw
o
w
o
m
e
n
(o
n
e
tr
e
at
e
d
w
it
h
D
H
P
an
d
th
e
o
th
e
r
w
it
h
IV
A
rt
).
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
8
4
9
7
6
.t
0
0
1
DHA-Piperaquine in Pregnancy
PLOS ONE | www.plosone.org 4 January 2014 | Volume 9 | Issue 1 | e84976
impending adverse outcomes (817, 12.5%). In 11 patients the
reason for admission was not documented.
Of the 6475 (99%) pregnant women screened for malaria, 1682
(26%) had a peripheral parasitaemia, 1050 (16.2%) with P.
falciparum, 456 (7%) with P. vivax 62 (3.7%) with P. malariae, one
with P. ovale and 113 (1.7%) with mixed infections (mostly P.
falciparum and P. vivax). In total 893 (53%) women with malaria
were symptomatic (fever or history of fever), with severe disease
recorded in 106 (6.3%). Of those with severe disease, 73% (77) had
P. falciparum infections, with the remaining equally distributed
between P. vivax (10), P. malariae (9), and mixed infections (10). The
most common manifestation of severity was severe anemia
(hemoglobin ,7 g/dl), present in 81 (76%) women. The maternal
mortality ratio was 324 per 100,000 live births (11/3,398 live
births) overall and 298 per 100,000 live births (5/1680) in women
Figure 2. Study Profile: Pregnant Women Delivering with Prior Febrile Illness.
doi:10.1371/journal.pone.0084976.g002
Table 2. Baseline characteristic of pregnant women delivering with prior history of last antimalarial exposure.
Characteristic
No history of
malaria (n =4408)
CQ±SP
(n =24)
Oral Qu
(n=347)
DHP alone
(n =336)
IV Art +/2 DHP
(n=77)
Age, mean year (95%CI of mean) 25.9 (25.8–26.1)a 23.7 (21.3–26.2) 25.4 (24.8–26.0) 24.8 (24.1–25.4) 24.6 (23.3–25.9)
Papuan Ethnic groups 64.7% (2846/4399)a 75% (18/24) 61.6% (213/346) 83% (279/336)c 71.4% (55/77)
Primigravidae 31% (1365/4404)b 45.8% (11/24) 37% (129/347) 32.4% (109/336) 39% (30/77)
Gestation of pregnancy, median week (range) 39 (19–44)a 39 (34–40) 39 (20–43) 38 (24–44) 38 (21–41)d
Febrile at delivery 5.2% (231/4406)a 33.3% (8/24) 28% (97/347) 10.7% (36/336)c,e 9% (7/77)c,e
Number of febrile episodes during pregnancy,
median no. (range)
- 1 (1–2) 1 (1–8) 1 (1–7)e 1 (1–4)e
Time from last exposure to delivery, median
weeks (range)
- 16 (1–35) 12 (1–39) 10 (1–29)c,e 10 (1–23)d
Notes: Compared with prior history of last antimalarial exposure:
ap,0.001,
bp,0.05; Compared with Oral Quinine:
cp#0.001,
dp,0.05; Compared with CQ+/2SP:
ep,0.05.
doi:10.1371/journal.pone.0084976.t002
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with malaria. Three of these malaria-associated maternal deaths
were infected with P. falciparum and the other two with P. vivax.
Exposure to antimalarial medications in the current
episode of malaria
A total of 1217 women in the second and third trimester had
detectable peripheral parasitemia, presented to hospital without
impending adverse outcomes; Figure 1. Of these 97 (7.9%) were
treated with CQ+/2SP, 271 (22%) with oral/IV Quinine, 486
(40%) with DHP alone and 363 (30%) with intravenous artesunate
with or without DHP.
Of the 525 mothers admitted for the treatment of malaria, 93%
(384/413) of those receiving an arteminisin based treatment (oral
DHP or intravenous artesunate) were discharged with an ongoing
pregnancy compared to 84% (96/114) of those receiving a non
artemisinin treatment (Odds Ratio = 2.48 [1.26–4.86]); p = 0.006.
The difference was most apparent in the risk of neonatal death in
patients receiving oral treatment in whom none (0/107) of their
babies of mothers treated with DHP had early neonatal death,
compared 6.5% (3/46) of babies born of mothers treated with oral
quinine (p = 0.026, Table 1); this difference remained after
controlling for baseline confounding factors (maternal age, ethnic
groups, parity, fever and severity status): Adjusted Odds Ratio
(AOR) = 0.2 [95%CI, 0.49–0.87], p= 0.032.
An additional 124 women were diagnosed and treated for
malaria but subsequently found to be aparasitaemic. The 93
women presenting without an impending adverse outcome (2 Cq/
SP, 13 Quinine and 78 DHP) had all been admitted for delivery
and delivered live babies.
Of the 332 women admitted in the first trimester, 152 (45.8%)
were found to have a peripheral parasitemia, and 41 of these
women had impending miscarriage at the time of presentation. In
two cases antimalarial treatment was not documented. Of the
remaining 109 women 8 (7.3%) miscarried, the risk being 2.6%
(1/38) in those receiving oral quinine compared to 62.5% (5/8) in
those treated with an oral DHP; p,0.001. None of the 60 women
receiving intravenous therapy miscarried (50 with intravenous
quinine, 5 with intravenous artesunate plus DHP and 5 with
intravenous artesunate alone).
History of prior antimalarial medication
The outcome of pregnancy could be determined in 5292
(81.7%) women, of whom 884 (16.7%) reported a history of febrile
illness during the pregnancy. Nearly all (847, 96%) of these women
were able to state their prior malaria treatment, and in 404
(47.7%) cases the diagnosis and treatment could be confirmed
from hospital records with .95% concordance (Figure 2).
Compared to women without any history of febrile illness, those
with prior febrile illness were more likely to be younger, Papuan
and primigravidae (Table 2).
Prior drug exposure during the same pregnancy for peripheral
parasitaemia, ranged from 1 to 8 episodes, although the majority
of women had a single antimalarial exposure (76%, 648/847); 122
women had multiple exposures with the same drug and 77
received different drugs, which were mostly quinine treatment
followed by DHP (61%, 47/77). The potential effect of drug
exposure to pregnancy outcome was assessed according to the last
anti-malarial exposure controlling for multiple exposure. The last
treatment of malaria was documented in 784 women of whom 102
(13%) were exposed in the first trimester, 238 (30%) in the second
trimester and 441 (56%) in the third trimester of pregnancy. For
three women the timing of exposure was unknown. Women with
prior exposure to DHP were more likely to have received
treatment closer to delivery and to be afebrile on admission
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compared to those treated with past CQ and oral Quinine
(Table 2). There were no other significant differences in baseline
characteristics between women exposed to different antimalarial
regimens.
Women reporting prior febrile illness were at significantly
greater risk of parasitemia at delivery compared to those with no
febrile history (OR=3.65 [95%CI, 3.07–4.34], p,0.001). The
risk of parasitemia at delivery was 26% (86/336) in women with
prior DHP treatment compared to 48% (178/370) of those
previously treated with oral quinine or CQ+/2SP; OR=0.37
(95%CI 0.27–0.52), p,0.001, Table 3 and figure 3. This
difference remained significant in the multivariate model
(AOR=0.48 [95%CI, 0.35–0.66], p,0.001). The lower risk of
parasitemia at delivery following DHP was apparent for both P.
falciparum (OR=0.34 [95%CI, 0.24–0.49], p,0.001) and P. vivax
(OR=0.6 [95%CI, 0.37–0.96], p = 0.034). The median time from
last treatment to representation with malaria was 11 weeks [range:
1–27] following DHP treatment compared to 8 weeks [range: 1–
37], following non ACT therapy, p = 0.05.
Prior antimalarial exposure was a significant risk factor for
adverse pregnancy outcomes compared to those without any
history of malaria during pregnancy (Table 3). The risk of
perinatal death was 6.6% (23/347) in babies born to women with
prior quinine exposure compared to 3.3% (11/336) in those born
of mothers previously treated with oral DHP, and an adjusted
Odds Ratio of 3.17 [95%CI: 1.17–8.60] after controlling for
confounding factors; p = 0.023 (Table 3 and 4). There was also a
significant difference in the risk of congenital malaria which was
greater in women with a history of prior quinine exposure
compared to those exposed to DHP (OR=15.8 [95%CI, 2.1–
121], p = 0.001) (Table 3), although this was not apparent in the
multivariate analysis (Table 4).
Discussion
In Papua Indonesia both P. falciparum and P. vivax infections
occur in approximately 20% of pregnant women and, even when
asymptomatic, are associated with an increased risk of maternal
anemia, still birth, prematurity, low birth weight and perinatal
death [9]. Treatment options are limited since high grade
multidrug resistance has emerged in both P. falciparum and P.
vivax to chloroquine, amodiaquine, and sulfadoxine-pyrimeth-
amine [11,24,25]. Antimalarial resistance is described less
frequently with quinine, however the prolonged thrice daily
treatment regimen is associated with poor adherence and
unacceptable effectiveness, which is likely to contribute signifi-
cantly to detrimental outcomes on both mother and baby. In areas
where adherence to a complete course of treatment cannot be
assured and multidrug resistance is rising, the use of these
conventional treatments demands careful scrutiny. The necessary
revision of the local district antimalarial policy in Timika in March
2006, saw the introduction of dihydroartemisinin-piperaquine
(DHP) for the treatment of uncomplicated malaria due to any
species, including the second and third trimesters of pregnancy.
Our study allowed us to review 1217 pregnant women treated with
antimalarial drugs including more than 760 women with antenatal
exposure to DHP.
In the second and third trimesters mothers the outcomes
following treatment with oral DHP were at least as good as those
for women treated with oral quinine. Infact in those presenting
with a febrile illness, DHP resulted in a 2.5 fold greater likelihood
of being discharged from hospital with an ongoing pregnancy
compared to women receiving oral quinine. The policy switch
from quinine to DHP for uncomplicated malaria in March 2006
was associated with a significant reduction in the risk of early
neonatal death from 6.5% (3/46) to zero (0/107). Significant
differences were also apparent in pregnant women with a history
of prior antimalarial exposure. Compared to women previously
treated with chloroquine or quinine, those treated with DHP had a
lower risk of malaria at delivery (OR=0.37), an effect that
extended for treatment up to 9 weeks prior to delivery (Figure 3).
This differential effect may reflect a number of factors including
the proven efficacy of DHP against the drug resistant isolates of
Figure 3. The proportion of women with peripheral parasitaemia at the time of delivery according to the timing of prior
antimalarial treatment.
doi:10.1371/journal.pone.0084976.g003
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both P. falciparum and P. vivax prevalent in this region, as well as the
prolonged post treatment prophylaxis afforded by piperaquine’s
long terminal elimination half life (,28 days) apparent in non
pregnant [26] and pregnant women [27]. Although a 7 day
regimen of quinine given three times per days may have adequate
efficacy when supervised, it reliably causes unpleasant side effects
and patients rarely adhere to a complete treatment course. The
poor adherence to quinine has major implications for high rates of
recrudescent infection and its short elimination half life provides
minimal post treatment prophylaxis against new and relapsing
infections. Our results suggest the increased risk of recurrent
parasitemia following quinine was associated with a significantly
greater risk of perinatal mortality and congenital malaria.
In the first trimester the risk of abortion was over 60% in
women receiving an ACT (7/11) compared to only 1% (1/38) in
women treated with quinine. Interestingly none of the 10 women
receiving IV artesunate, either with and without DHP, miscarried.
The markedly higher rates of abortion in women with first
trimester exposure to DHP is of concern, and although this may
signify drug toxicity, it may also reflect intrinsic biases within our
non-comparative observational study. The abortion risk of women
treated with quinine in our study was significantly lower than that
described in women on the Thai-Burmese border (25%) [28]
suggesting a possible systematic bias in prescribing alternative
medication in this risk group. Anecdotal evidence indicates that in
our study prescription of oral DHP alone in the first trimester was
reserved for those women who were more unwell, even though this
was not recommended in local protocols and this may explain the
poor outcome.
There are a number of limitations to our study. Following policy
change in 2006, it was not deemed acceptable to randomize
women to treatments known to be partially effective, hence our
study is reliant on historical comparison and all the confounding
factors inherent within that. Although multivariable analysis was
applied to control for confounders, other unrecorded factors will
not have been included and a degree of residual confounding is
likely to have contributed for some of the differences in outcomes
observed. However our analysis represents one of the largest
observational studies to date of the use of DHP in pregnancy and
provides reassuring data that in the second and third trimesters its
use is associated with outcomes at least as good that following
quinine. Furthermore the simple three day treatment regimen has
pragmatic implications for adherence properties and when
combined with the slow elimination of piperaquine it resulted in
a significant reduction in recurrent parasitaemia with associated
benefits for both maternal and neonatal outcomes. As such these
observations provide reassuring data and an incentive for further
comparative studies of DHP in pregnancy, including a potential
role for DHP as a novel intermittent presumptive therapy [29].
Another limitation was the use of information of prior
antimalarial exposure derived from questioning of the mother
and thus vulnerability to recall bias. We used a systematic
interview method to obtain information on the timing of exposures
(approximate pregnancy gestational age in months) and treatment
received (shape and colour of the tablets). Our experience has
shown that women in this region are familiar with the various
available antimalarial drugs and this was confirmed by very high
concordance between the interview results and the actual drug
received in women whose medical record were available.
Reassuringly in a sensitivity analysis in which the data were
restricted to the women in whom documentation could be
confirmed from hospital records, the observations of adverse
outcomes were similar.
Pregnant women were not routinely followed up following
antimalarial exposure and documentation of birth outcome could
only be made in 17% of pregnant women exposed to antimalarials
on hospital admission and discharged with ongoing pregnancy.
We can not discount the possibility of women exposed to DHP
Table 4. Predictors for Adverse Outcomes.
Predictors
Maternal Malaria
at delivery
Maternal severe
anemia
Low Birth
weight
Preterm
delivery Perinatal death Congenital malaria
Maternal Malaria at delivery - 3.03 (1.83–5.01),
p,0.001
2.08 (1.34–3.22),
p = 0.001
1.74 (1.06–2.87),
p = 0.029
2.43 (1.10–5.39),
p = 0.029
3.25 (0.56–19.06), p = 0.191
Maternal severe anemia 3.05 (1.83–5.07),
p,0.001
- 2.61 (1.57–4.33),
p,0.001
2.01 (1.13–3.55),
p = 0.018
1.22 (0.47–3.15),
p = 0.684
1.29 (0.32–5.16), p = 0.721
Fever/History of fever 9.04 (5.62–14.53),
p,0.001
0.78 (0.44–1.39),
p = 0.404
1.38 (0.83–2.29),
p = 0.208
2.45 (1.39–4.29),
p = 0.002
0.93 (0.38–2.28),
p = 0.881
1.48 (0.47–4.68), p = 0.508
Primigravidae 1.17 (0.78–1.76),
p = 0.448
1.05 (0.62–1.78),
p = 0.868
2.56 (1.63–4.02),
p,0.001
2.16 (1.31–3.54),
p = 0.002
1.87 (0.83–4.23),
p = 0.132
0.52 (0.14–1.97), p = 0.336
Papuan Ethnicity 1.23 (0.82–1.85),
p = 0.322
2.42 (1.25–4.68),
p = 0.009
0.99 (0.62–1.59),
p = 0.975
0.92 (0.55–1.56),
p = 0.757
2.66 (0.99–7.12),
p = 0.051
0.68 (0.19–2.48), p = 0.560
Maternal age #18 y.o 0.97 (0.93–1.00),
p = 0.065
0.97 (0.92–1.01),
p = 0.152
1.0 (0.96–1.04),
p = 0.910
0.99 (0.95–1.04),
p = 0.856
1.02 (0.95–1.09),
p = 0.567
1.04 (0.95–1.14), p = 0.421
Prior Treatment Exposures
CQ+/2 SP 1.52 (0.51–4.49),
p = 0.450
0.87 (0.24–3.18),
p = 0.831
1.03 (0.33–3.16),
p = 0.966
1.10 (0.33–3.71),
p = 0.874
- 0.87 (0.03–23.44), p = 0.933
Qu+/2IV Qu 1.56 (0.97–2.50),
p = 0.068
0.75 (0.39–1.48),
p = 0.411
0.90 (0.52–1.55),
p = 0.707
0.59 (0.32–1.1),
p = 0.097
3.17 (1.17–8.60),
p = 0.023
1.16 (0.09–14.64), p = 0.909
IV Art+/2DHP 1.13 (0.61–2.12),
p = 0.690
0.89 (0.39–2.07),
p = 0.798
0.69 (0.32–1.45),
p = 0.325
1.02 (0.49–2.10),
p = 0.967
0.94 (0.19–4.45),
p = 0.938
-
DHP alone 1 1 1 1 1 1
Footnote: Adjusted Odds Ratio (95% Confidence intervals) are presented. In all multivariate models cofactors were entered into the model after stratifying by year of
exposure.
doi:10.1371/journal.pone.0084976.t004
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having adverse outcomes away from hospital, however it is likely
to be similar for DHP as for chloroquine and quinine. The
comparison between treatments therefore provides a useful
indication of relative adverse outcomes which in the second and
third trimesters were in favour of DHP. Finally the lack of
prospective follow up limited our ability to define precisely the
efficacy of treatment regimens, although recurrence at represen-
tation to hospital was significantly lower in patients receiving DHP
compared to chloroquine.
In conclusion, our results show that the early diagnosis and
prompt treatment with DHP in the second and third trimesters of
pregnancy reduces recurrent malaria and is associated with as fall
in perinatal death and congenital malaria. Further prospective
randomised controlled trials of DHP in pregnant women are
needed to confirm these findings and complementary pharmaco-
kinetic studies to ensure the optimal deployment of this important
antimalarial in antenatal practice. The increased rates of abortion
in women with exposure in the first trimester is of concern, and
although this may reflect bias within our observational study, the
use of DHP in the first trimester should continue to be avoided
until further safety information is available.
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